Biomarkers, the control panel and personalized COPD medicine

Respirology

Volumn 21, Issue 1, 2016, Pages 24-33

  Agusti, Alvar ^a,b,c   Gea, Joaquim ^b,d   Faner, Rosa ^b,c  

^a UNIVERSITY OF BARCELONA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^d UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

chronic bronchitis; emphysema; inflammation; network analysis; smoking

Indexed keywords

BIOLOGICAL MARKER;

CHRONIC OBSTRUCTIVE LUNG DISEASE; DAILY LIFE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC SUSCEPTIBILITY; HUMAN; METABOLOMICS; PATIENT CARE; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REVIEW; SMOKING; SPUTUM EXAMINATION; TRANSCRIPTOMICS; BLOOD; GENETICS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TRENDS;

BIOMARKERS; HUMANS; PRECISION MEDICINE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84951076252     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.12585     Document Type: Review

References (81)

1. Vrijheid M,. The exposome: a new paradigm to study the impact of environment on health. Thorax 2014; 69: 876-878.
2. Lotvall J, Akdis CA, Bacharier LB, Bjermer L, Casale TB, Custovic A, Lemanske RF Jr, Wardlaw AJ, Wenzel SE, Greenberger PA,. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J. Allergy Clin. Immunol. 2011; 127: 355-360.
3. Woodruff PG, Agusti A, Roche N, Singh D, Martinez FJ,. Current concepts in COPD pharmacological treatment: the GOLD (r)evolution and endotype-driven therapy. Lancet 2015 (in press).
4. Agusti A, Calverley P, Celli B, Coxson H, Edwards L, Lomas D, MacNee W, Miller B, Rennard S, Silverman E, et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir. Res. 2010; 11: 122-136.
5. Agusti A,. The path to personalized medicine in COPD. Thorax 2014; 69: 857-864.
6. Agusti A, Anto JM, Auffray C, Barbe F, Barreiro E, Dorca J, Escarrabill J, Faner R, Furlong LI, Garcia-Aymerich J, et al. Personalized respiratory medicine: exploring the horizon, addressing the issues. Am. J. Respir. Crit. Care Med. 2015; 191: 391-401.
7. Han MK, Agusti A, Calverley PM, Celli BR, Criner G, Curtis JL, Fabbri LM, Goldin JG, Jones PW, MacNee W, et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am. J. Respir. Crit. Care Med. 2010; 182: 598-604.
8. Agusti A,. Phenotypes and disease characterization in chronic obstructive pulmonary disease. Toward the extinction of phenotypes? Ann Am Thorac Soc. 2013; 10: S125-130.
9. Agusti A, MacNee W,. The COPD control panel: towards personalised medicine in COPD. Thorax 2013; 68: 687-690.
10. Jones PW, Agusti AGN,. Outcomes and markers in the assessment of chronic obstructive pulmonary disease. Eur. Respir. J. 2006; 27: 822-832.
11. Agusti A, Sobradillo P, Celli B,. Addressing the complexity of chronic obstructive pulmonary disease: from phenotypes and biomarkers to scale-free networks, systems biology, and P4 medicine. Am. J. Respir. Crit. Care Med. 2011; 183: 1129-1137.
12. Agusti A, Celli B,. Avoiding confusion in COPD: from risk factors to phenotypes to measures of disease characterisation. Eur. Respir. J. 2011; 38: 749-751.
13. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, Van Weel C, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am. J. Respir. Crit. Care Med. 2007; 176: 532-555.
14. Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, Barnes PJ, Fabbri LM, Martinez FJ, Nishimura M, et al. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease, GOLD executive summary. Am. J. Respir. Crit. Care Med. 2013; 187: 347-365.
15. Casanova C, Cote C, de Torres JP, Aguirre-Jaime A, Marin JM, Pinto-Plata V, Celli BR,. Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2005; 171: 591-597.
16. Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, Pinto Plata V, Cabral HJ,. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N. Engl. J. Med. 2004; 350: 1005-1012.
17. Puhan MA, Garcia-Aymerich J, Frey M, Ter RG, Anto JM, Agusti AG, Gomez FP, Rodriguez-Roisin R, Moons KG, Kessels AG, et al. Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index. Lancet 2009; 374: 704-711.
18. Mannino DM, Thorn D, Swensen A, Holguin F,. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur. Respir. J. 2008; 32: 962-969.
19. Grosdidier S, Ferrer A, Faner R, Pinero J, Roca J, Cosio B, Agusti A, Gea J, Sanz F, Furlong LI,. Network medicine analysis of COPD multimorbidities. Respir. Res. 2014; 15: 111.
20. Vestbo J, Rennard S,. Chronic obstructive pulmonary disease biomarker(s) for disease activity needed-urgently. Am. J. Respir. Crit. Care Med. 2010; 182: 863-864.
21. Agusti A, Vestbo J,. Current controversies and future perspectives in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2011; 184: 507-513.
22. Vilaplana C, Cardona PJ,. The lack of a big picture in tuberculosis: the clinical point of view, the problems of experimental modeling and immunomodulation. The factors we should consider when designing novel treatment strategies. Front Microbiol. 2014; 5: 55.
23. Vestbo J, Edwards LD, Scanlon PD, Yates JC, Agusti A, Bakke P, Calverley PMA, Celli B, Coxson HO, Crim C, et al. Changes in forced expiratory volume in 1 second over time in COPD. N. Engl. J. Med. 2011; 365: 1184-1192.
24. Jenkins CR, Jones PW, Calverley PM, Celli B, Anderson JA, Ferguson GT, Yates JC, Willits LR, Vestbo J,. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir. Res. 2009; 10: 59.
25. Decramer M, Celli B, Kesten S, Lystig T, Mehra S, Tashkin DP,. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet 2009; 374: 1171-1178.
26. Coxson HO, Dirksen A, Edwards L, Yates JC, Agusti A, Bakke P, Calverley PMA, Celli B, Crim C, Lomas DA, et al. The presence and progression of emphysema in COPD as determined by CT scanning and biomarker expression: a prospective analysis from the ECLIPSE study. Lancet Respir Med. 2013; 1: 129-136.
27. Anthonisen NR, Connett JE, Murray RP,. Smoking and lung function of Lung Health Study participants after 11 years. Am. J. Respir. Crit. Care Med. 2002; 166: 675-679.
28. Hurst JR, Vestbo J, Anzueto A, Locantore N, Mullerova H, Tal-Singer R, Miller B, Lomas DA, Agusti A, MacNee W, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N. Engl. J. Med. 2010; 363: 1128-1138.
29. Schols AM, Broekhuizen R, Weling-Scheepers CA, Wouters EF,. Body composition and mortality in chronic obstructive pulmonary disease. Am. J. Clin. Nutr. 2005; 82: 53-59.
30. Agusti A, Sin DD,. Biomarkers in COPD. Clin. Chest Med. 2014; 35: 131-141.
31. Davis SQ, Permutt Z, Permutt S, Naureckas ET, Bilderback AL, Rand CS, Stein BD, Krishnan JA,. Perception of airflow obstruction in patients hospitalized for acute asthma. Ann. Allergy Asthma Immunol. 2009; 102: 455-461.
32. Faner R, Tal-Singer R, Riley JH, Celli B, Vestbo J, MacNee W, Bakke P, Calverley PMA, Coxson H, Crim C, et al. Lessons from ECLIPSE: a review of COPD biomarkers. Thorax 2014; 69: 666-672.
33. Singh D, Edwards L, Tal-Singer R, Rennard S,. Sputum neutrophils as a biomarker in COPD: findings from the ECLIPSE study. Respir. Res. 2010; 11: 77.
34. Agusti A, Edwards LD, Rennard SI, MacNee W, Tal-Singer R, Miller BE, Vestbo J, Lomas DA, Calverley PMA, Wouters E, et al. persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS ONE 2012; 7: e37483.
35. Celli BR, Locantore N, Yates J, Tal-Singer R, Miller BE, Bakke P, Calverley P, Coxson H, Crim C, Edwards LD, et al. Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2012; 185: 1065-1072.
36. Duvoix A, Dickens J, Haq I, Mannino D, Miller B, Tal-Singer R, Lomas DA,. Blood fibrinogen as a biomarker of chronic obstructive pulmonary disease. Thorax 2013; 68: 670-676.
37. Casaburi R, Celli B, Crapo J, Criner G, Croxton T, Gaw A, Kline-Leidy N, Lomas DA, Merrill D, Polkey MI, et al. The COPD Biomarker Qualification Consortium (CBQC). COPD 2013; 10: 367-377.
38. Lomas DA, Silverman EK, Edwards LD, Miller BE, Coxson HO, Tal-Singer R,. Evaluation of serum CC-16 as a biomarker for COPD in the ECLIPSE cohort. Thorax 2008; 63: 1058-1063.
39. Hanania NA, Mullerova H, Locantore NW, Vestbo J, Watkins ML, Wouters EF, Rennard SI, Sharafkhaneh A,. Determinants of depression in the ECLIPSE chronic obstructive pulmonary disease cohort. Am. J. Respir. Crit. Care Med. 2011; 183: 604-611.
40. Lomas DA, Silverman EK, Edwards LD, Locantore NW, Miller BE, Horstman DH, Tal-Singer R, Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints study investigators. Serum surfactant protein D is steroid sensitive and associated with exacerbations of COPD. Eur. Respir. J. 2009; 34: 95-102.
41. Sin DD, Miller BE, Duvoix A, Man SFP, Zhang X, Silverman EK, Connett JE, Anthonisen NA, Wise RA, Tashkin D, et al. Serum PARC/CCL-18 concentrations and health outcomes in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2011; 183: 1187-1192.
42. Cheng DT, Kim DK, Cockayne DA, Belousov A, Bitter H, Cho MH, Duvoix A, Edwards LD, Lomas DA, Miller BE, et al. Systemic sRAGE is a biomarker of emphysema and associated with AGER genetic variants in COPD Patients. Am. J. Respir. Crit. Care Med. 2013; 188: 948-957.
43. Miller J, Edwards LD, Agusti A, Bakke P, Calverley PM, Celli B, Coxson HO, Crim C, Lomas DA, Miller BE, et al. Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respir. Med. 2013; 107: 1376-1384.
44. Breyer MK, Rutten EP, Locantore NW, Watkins ML, Miller BE, Wouters EF,. Dysregulated adipokine metabolism in chronic obstructive pulmonary disease. Eur. J. Clin. Invest. 2012; 42: 983-991.
45. Berg I, Hanson C, Sayles H, Romberger D, Nelson A, Meza J, Miller B, Wouters EF, MacNee W, Rutten EP, et al. Vitamin D, vitamin D binding protein, lung function and structure in COPD. Respir. Med. 2013; 107: 1578-1588.
46. Siedlinski M, Cho MH, Bakke P, Gulsvik A, Lomas DA, Anderson W, Kong X, Rennard SI, Beaty TH, Hokanson JE, et al. Genome-wide association study of smoking behaviours in patients with COPD. Thorax 2011; 66: 894-902.
47. Pillai SG, Kong X, Edwards LD, Cho M, Anderson WH, Coxson HO, Lomas DA, Silverman EK,. Loci identified by genome-wide association studies influence different disease-related phenotypes in COPD. Am. J. Respir. Crit. Care Med. 2010; 182: 1498-1505.
48. Kong X, Cho MH, Anderson W, Coxson HO, Muller N, Washko G, Hoffman EA, Bakke P, Gulsvik A, Lomas DA, et al. Genome-wide association study identifies BICD1 as a susceptibility gene for emphysema. Am. J. Respir. Crit. Care Med. 2010; 183: 43-49.
49. Wan ES, Cho MH, Boutaoui N, Klanderman BJ, Sylvia JS, Ziniti JP, Won S, Lange C, Pillai SG, Anderson WH, et al. Genome-wide association analysis of body mass in chronic obstructive pulmonary disease. Am. J. Respir. Cell Mol. Biol. 2011; 45: 304-310.
50. Kim DK, Cho MH, Hersh CP, Lomas DA, Miller BE, Kong X, Bakke P, Gulsvik A, Agusti A, Wouters E, et al. Genome-wide association analysis of blood biomarkers in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2012; 186: 1238-1247.
51. Singh D, Fox SM, Tal-Singer R, Plumb J, Bates S, Broad P, Riley JH, Celli B,. Induced sputum genes associated with spirometric and radiological disease severity in COPD ex-smokers. Thorax 2011; 66: 489-495.
52. Qiu W, Cho MH, Riley JH, Anderson WH, Singh D, Bakke P, Gulsvik A, Litonjua AA, Lomas DA, Crapo JD, et al. Genetics of sputum gene expression in chronic obstructive pulmonary disease. PLoS ONE 2011; 6: e24395.
53. Ubhi BK, Riley JH, Shaw PA, Lomas DA, Tal-Singer R, MacNee W, Griffin JL, Connor SC,. Metabolic profiling detects biomarkers of protein degradation in COPD patients. Eur. Respir. J. 2012; 40: 345-355.
54. Ubhi BK, Cheng KK, Dong J, Janowitz T, Jodrell D, Tal-Singer R, MacNee W, Lomas DA, Riley JH, Griffin JL, et al. Targeted metabolomics identifies perturbations in amino acid metabolism that sub-classify patients with COPD. Mol. Biosyst. 2012; 8: 3125-3133.
55. MacNee W, Rennard SI, Hunt JF, Edwards LD, Miller BE, Locantore NW, Tal-Singer R,. Evaluation of exhaled breath condensate pH as a biomarker for COPD. Respir. Med. 2011; 105: 1037-1045.
56. Esther CR Jr, Lazaar AL, Bordonali E, Qaqish B, Boucher RC,. Elevated airway purines in COPD. Chest 2011; 140: 954-960.
57. Thomsen M, Ingebrigtsen TS, Marott JL, Dahl M, Lange P, Vestbo J, Nordestgaard BG,. Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. JAMA 2013; 309: 2353-2361.
58. Singh D, Kolsum U, Brightling CE, Locantore N, Agusti A, Tal-Singer R,. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. Eur. Respir. J. 2014; 44: 1697-1700.
59. Laucho-Contreras ME, Polverino F, Gupta K, Taylor KL, Kelly E, Pinto-Plata V, Divo M, Ashfaq N, Petersen H, Stripp B, et al. Protective role for club cell secretory protein-16 (CC16) in the development of chronic obstructive pulmonary disease. Eur. Respir. J. 2015; 45: 1544-1556.
60. Lomas DA, Silverman EK,. The genetics of chronic obstructive pulmonary disease. Respir. Res. 2001; 2: 20-26.
61. Faner R, Rojas M, MacNee W, Agusti A,. Abnormal lung aging in chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2012; 186: 306-313.
62. Rabe KF, Fabbri LM, Israel E, Kogler H, Riemann K, Schmidt H, Glaab T, Vogelmeier CF,. Effect of ADRB2 polymorphisms on the efficacy of salmeterol and tiotropium in preventing COPD exacerbations: a prespecified substudy of the POET-COPD trial. Lancet Respir Med. 2014; 2: 44-53.
63. Barnes PJ,. Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease. J. Allergy Clin. Immunol. 2013; 131: 636-645.
64. Qiu W, Baccarelli A, Carey VJ, Boutaoui N, Bacherman H, Klanderman B, Rennard S, Agusti A, Anderson W, Lomas DA, et al. Variable DNA methylation is associated with chronic obstructive pulmonary disease and lung function. Am. J. Respir. Crit. Care Med. 2012; 185: 373-381.
65. Wan ES, Qiu W, Baccarelli A, Carey VJ, Bacherman H, Rennard SI, Agusti A, Anderson WH, Lomas DA, DeMeo DL,. Systemic steroid exposure is associated with differential methylation in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2012; 186: 1248-1255.
66. Ezzie ME, Crawford M, Cho JH, Orellana R, Zhang S, Gelinas R, Batte K, Yu L, Nuovo G, Galas D, et al. Gene expression networks in COPD: microRNA and mRNA regulation. Thorax 2012; 67: 122-131.
67. Wang M, Huang Y, Liang Z, Liu D, Lu Y, Dai Y, Feng G, Wang C,. Plasma miRNAs might be promising biomarkers of chronic obstructive pulmonary disease. Clin Respir J. 2014; doi: 10.1111/crj.12194. [Epub ahead of print].
68. Morrow JD, Qiu W, Chhabra D, Rennard SI, Belloni P, Belousov A, Pillai SG, Hersh CP,. Identifying a gene expression signature of frequent COPD exacerbations in peripheral blood using network methods. BMC Med Genomics. 2015; 8: 1.
69. Basanta M, Jarvis RM, Xu Y, Blackburn G, Tal-Singer R, Woodcock A, Singh D, Goodacre R, Thomas CL, Fowler SJ,. Non-invasive metabolomic analysis of breath using differential mobility spectrometry in patients with chronic obstructive pulmonary disease and healthy smokers. Analyst 2010; 135: 315-320.
70. Sibila O, Garcia-Bellmunt L, Giner J, Merino JL, Suarez-Cuartin G, Torrego A, Solanes I, Castillo D, Valera JL, Cosio BG, et al. Identification of airway bacterial colonization by an electronic nose in chronic obstructive pulmonary disease. Respir. Med. 2014; 108: 1608-1614.
71. Seemungal TA, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA,. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2000; 161: 1608-1613.
72. Garcia-Aymerich J, Gomez FP, Benet M, Farrero E, Basagana X, Gayete A, Pare C, Freixa X, Ferrer J, Ferrer A, et al. Identification and prospective validation of clinically relevant chronic obstructive pulmonary disease (COPD) subtypes. Thorax 2011; 66: 430-437.
73. Watz H, Waschki B, Meyer T, Magnussen H,. Physical activity in patients with COPD. Eur. Respir. J. 2009; 33: 262-272.
74. Waschki B, Kirsten A, Holz O, Muller KC, Meyer T, Watz H, Magnussen H,. Physical activity is the strongest predictor of all-cause mortality in patients with COPD: a prospective cohort study. Chest 2011; 140: 331-342.
75. Diez D, Agusti A, Wheelock CE,. Network analysis in the investigation of chronic respiratory diseases: from basics to application. Am. J. Respir. Crit. Care Med. 2014; 190: 981-988.
76. Bauer-Mehren A, Furlong LI, Sanz F,. Pathway databases and tools for their exploitation: benefits, current limitations and challenges. Mol. Syst. Biol. 2009; 5: 290-296.
77. Divo M, Cote C, de Torres JP, Casanova C, Marin JM, Pinto-Plata V, Zulueta J, Cabrera C, Zagaceta J, Hunninghake G, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2012; 186: 155-161.
78. Bousquet J, Anto J, Sterk P, Adcock I, Chung K, Roca J, Agusti A, Brightling C, Cambon-Thomsen A, Cesario A, et al. Systems medicine and integrated care to combat chronic noncommunicable diseases. Genome Med. 2011; 3: 43-55.
79. Bousquet J, Addis A, Adcock I, Agache I, Agusti A, Alonso A, Annesi-Maesano I, Anto JM, Bachert C, Baena-Cagnani CE, et al,. Integrated care pathways for airway diseases (AIRWAYS-ICPs). Eur. Respir. J. 2014; 44: 304-323.
80. Barabasi AL, Gulbahce N, Loscalzo J,. Network medicine: a network-based approach to human disease. Nat. Rev. Genet. 2011; 12: 56-68.
81. Mirnezami R, Nicholson J, Darzi A,. Preparing for precision medicine. N. Engl. J. Med. 2012; 366: 489-491.